Please login to the form below

Ilaris

This page shows the latest Ilaris news and features for those working in and with pharma, biotech and healthcare.

Novartis withdraws EU filing for canakinumab

The decision is a further setback for this expansion in the use of canakinumab, which Novartis already markets as an inflammatory disease treatment under the brand name Ilaris.

Latest news

Novartis culls pipeline to focus on most transformative science

It recently hit problems with one of its most important late-stage programmes when the FDA refused to accept the filing of anti-inflammatory drug canakinumab (Ilaris) in cardiovascular risk reduction.
Daily Brief: EULAR kicks off, Brexit lurches closer and Autolus prepares for IPO

On today’s agenda expect new trial data from Novartis' Ilaris in gout, Lilly's Oluminant in systemic lupus and AbbVie's new JAK inhibitor upadacitinib.
CV data sets up Novartis' Ilaris for blockbuster sales

Drug shown to reduce major adverse cardiovascular events. Novartis has posted surprise phase III data that could transform the fortunes of its anti-inflammatory drug Ilaris, making it an option to ... The CANTOS study showed that the active ingredient in
Novartis' Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions. Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever Syndrome conditions. ... Paul Hudson, Novartis
Novartis wins childhood arthritis indication for Ilaris in EU

Novartis' inflammatory disease drug Ilaris (canakinumab) can be used more widely in the EU following its approval for the treatment of a rare form of childhood arthritis. ... The European Commission (EC) gave its final assent to Ilaris for the treatment

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest appointments

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

During his time at Novartis, de Vries led the discovery and early development of several drugs including Elidel (pimecrolimus) for eczema, Ilaris (canakunimab) for cryopyrin-associated periodic syndromes, Gilenya (fingolimod) for

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Associate Director: £75, 000-90, 000

Account Director – Health Policy – Global Agency: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Medical Writer: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager / Account Director: Competative

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Director – Healthcare Marketing – Berks: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director, Medical Education: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Medical Writer: Salary TBC

Global Business Development Director – Health Education: excellent commission

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Account Director development role to Business Director, H...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...